Heron Therapeutics (HRTX)

• Market cap: $193M
• 1 day: -1.56%
• 5 days: -3.08%
• 1 month: -3.82%
• 3 months: -37.31%
• 6 months: -47.72%
• Year to date: -21.25%
• 1 year: -31.52%
• 5 years: -91.97%
• 10 years: -96.6%
• Sector: Healthcare
• Industry: Biotechnology

About: Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.

Employees: 122

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

3,671% more call options, than puts

Call options by funds: $3.28M | Put options by funds: $87K

110% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 31

41% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 17

4.26% more ownership

Funds ownership: 81.91% [Q1] → 86.17% (+4.26%) [Q2]

4% more funds holding

Funds holding: 164 [Q1] → 170 (+6) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]

1% less capital invested

Capital invested by funds: $274M [Q1] → $272M (-$2.36M) [Q2]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $3
• Avg. target: $3
• High target: $3

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Needham Serge Belanger

$3

Buy Maintained

8 Aug 2025